Jump to content

Neuropeptide Y

From Wikipedia, the free encyclopedia
Not to be confused withPeptide YY.
NPY
Available structures
PDBOrtholog search:PDBeRCSB
Identifiers
AliasesNPY,PYY4, Neuropeptid Y gene, neuropeptide Y
External IDsOMIM:162640;MGI:97374;HomoloGene:697;GeneCards:NPY;OMA:NPY - orthologs
Orthologs
SpeciesHumanMouse
Entrez

4852

109648

Ensembl

ENSG00000122585

ENSMUSG00000029819

UniProt

P01303

P57774

RefSeq (mRNA)

NM_000905

NM_023456

RefSeq (protein)

NP_000896

NP_075945

Location (UCSC)Chr 7: 24.28 – 24.29 MbChr 6: 49.8 – 49.81 Mb
PubMedsearch[3][4]
Wikidata
View/Edit HumanView/Edit Mouse
Neuropeptide Y
Identifiers
CAS Number
ChemSpider
  • none
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC190H287N55O57
Molar mass4253.714g·mol−1
☒NcheckY(what is this?)(verify)

Neuropeptide Y(NPY) is a 36 amino-acid neuropeptide that is involved in various physiological and homeostatic processes in both the central and peripheral nervous systems. It is secreted alongside other neurotransmitters such asGABAandglutamate.[5][6][7][8]

In the autonomic system it is produced mainly byneuronsof thesympathetic nervous systemand serves as a strongvasoconstrictorand also causes growth of fat tissue.[9]In the brain, it is produced in various locations including thehypothalamus,and is thought to have several functions, including: increasing food intake and storage of energy as fat, reducing anxiety and stress, reducing pain perception, affecting thecircadian rhythm,reducing voluntary alcohol intake, lowering blood pressure, and controlling epileptic seizures.[8][10]

Function

[edit]

Neuropeptide Y has been identified as being synthesized inGABAergicneurons and to act as aneurotransmitterduringcellular communication.Neuropeptide Y is expressed ininterneurons.[11]NPY exerts most of its effects throughNeuropeptide Y receptors,mainlyY1,Y2,Y4,andY6.[7][8]All receptors have been indicated as participants inpost-synaptictransmission activity, but the Y2 receptor has also been found to be involved inpre-synapticprocessing.[6]

The receptor protein that NPY operates on is aG protein-coupled receptorin therhodopsinlike 7-transmembrane GPCR family. Five subtypes of the NPY receptor have been identified in mammals, four of which are functional in humans.[12]Subtypes Y1 and Y5 have known roles in the stimulation of feeding while Y2 and Y4 seem to have roles in appetite inhibition (satiety). Some of these receptors are among the most highly conservedneuropeptidereceptors[citation needed].

High concentrations of neuropeptide Y synthesis and action have been found in thehypothalamusandhippocampus,specifically in thearcuate nucleus(ARC) anddentate gyrus.The arcuate nucleus has been found to have one of the highest concentrations of NPY. This allows NPY to regulateneuroendocrinerelease of various hypothalamic hormones such asluteinizing hormone.[13]Neuropeptide Y1 receptors have been found in highest density in the dentate gyrus along with a variety of other brain areas.[14]

NPY is able to modulate the mitochondrial network by affecting the expression of many genes involved in mitochondrial functions and dynamics. It has been found that in breast muscle, ATP production genes (uncoupling protein,UCP;nuclear factor erythroid 2 like 2,NFE2L2) and a dynamics gene (mitofusin 1,MFN1) were upregulated (P< 0.05) at a low dose of NPY, while a high dose decreased (P< 0.05) markers of mitochondrial dynamics (mitofusin 2,MFN2;OPA1 mitochondrial dynamin-like GTPase,OPA1) and increased (P< 0.05) genes involved in mitochondrial biogenesis (D-loop, peroxisome proliferator-activated receptor gamma,PPARG).[15]

Cell growth

[edit]

Neuropeptide Y has been indicated as playing an important role inneurogenesisin various parts of the brain. Two particular brain areas where NPY affects neurogenesis are thesub-ventricular zoneand thedentate gyrusof thehippocampus.These areas are wherecell growthand proliferation occur intoadulthood.[16]

Dentate gyrus

[edit]

Thedentate gyrusis significantly involved incell proliferation,a process modulated by various internal factors including neuropeptide Y. Reduction or elimination of NPY released byinterneuronsdecreased cell growth in this brain area. NPY affects neurogenesis by interacting withERK kinase signaling pathways.[17]Additionally, NPY acting on and stimulating Y1 receptors present onprogenitor cellmembranes in order to increase cell proliferation.[16]

Sub-ventricular zone

[edit]

Similar to the dentate gyrus, NPY has been found to increase cellular proliferation anddifferentiationin thesub-ventricular zoneby specifically activating Y1 receptors in the ERK1/2 pathway. Additionally, NPY was found in neuronal fibers that pass through the sub-ventricular zone and extend to other brain areas. A variety of other effects and physiological processes involving NPY in the sub-ventricular zone have been discovered, many of which involveneuron migrationpatterns.[18]

Olfactory bulb

[edit]

It was found that after blocking NPY expression in mouseolfactory epithelium,the amount of olfactory precursor cells decreased by half. This in turn caused the mice to develop a lower amount ofolfactorycells overall. This study exemplified NPY's influence onprecursor cells.[19]

Discovery

[edit]

Following the isolation of neuropeptide Y (NPY) from theporcinehypothalamusin 1982, researchers began to speculate about the involvement of NPY in hypothalamic-mediated functions. In a 1983 study, NPY-ergic axon terminals were located in theparaventricular nucleus(PVN) of thehypothalamus,and the highest levels of NPY immunoreactivity was found within the PVN of the hypothalamus.[20]

Six years later, in 1989, Morris et al. homed in on the location of NPYergic nuclei in the brain. Furthermore,in situ hybridizationresults from the study showed the highest cellular levels of NPYmRNAin thearcuate nucleus(ARC) of the hypothalamus.[21]

In 1989, Haas & George reported that local injection of NPY into the PVN resulted in an acute release ofcorticotropin-releasing hormone(CRH) in the rat brain, proving that NPYergic activity directly stimulates the release and synthesis of CRH.[22]

The latter became a hallmark paper in NPY studies. A significant amount of work had already been done in the 1970s on CRH and its involvement in stress and eating disorders such asobesity.[23]These studies, collectively, marked the beginning for understanding the role of NPY inorexigenesisor food intake.

Connection to food intake

[edit]

Behavioral assays in orexigenic studies, in whichratsare the model organism, have been done collectively withimmunoassaysandin situ hybridizationstudies to confirm that elevating NPY-ergic activity does indeed increase food intake. In these studies, exogenous NPY,[24]theglucocorticoiddexamethasone(which activates NPY in the basomedial hypothalamus),[25]or N-acetyl [Leu 28, Leu31] NPY (24-36)[26]are injected into the third ventricle[24]or at the level of the hypothalamus with acannula.[25][27]

Furthermore, these studies unanimously demonstrate that the stimulation of NPYergic activity via the administration of certain NPYagonistsincreases food intake compared to baseline data in rats. The effects of NPYergic activity on food intake is also demonstrated by the blockade of certain NPY receptors (Y1 and Y5 receptors), which, as was expected, inhibited NPYergic activity; thus, decreases food intake. However, a 1999 study by King et al. demonstrated the effects of the activation of the NPY autoreceptor Y2, which has been shown to inhibit the release of NPY and thus acts to regulate food intake upon its activation.[28]In this study a highly selective Y2 antagonist, BIIE0246 was administered locally into the ARC. Radioimmunoassay data, following the injection of BIIE0246, shows a significant increase in NPY release compared to the control group. Though the pharmacological half-life of exogenous NPY, other agonists, and antagonist is still obscure, the effects are not long lasting and the rat body employs an excellent ability to regulate and normalize abnormal NPY levels and therefore food consumption.[24]

Connection to obesity

[edit]

A study in genetically obese rats demonstrated the role of NPY inobesity.[29]Four underlying factors that contribute to obesity in rats are:

In obesity chronically elevated levels of NPY can be seen, this has been seen in rats fed on a high fat diet for 22 weeks and resulted in a hormonal derangement that increased NPY release, due to a defective leptin signal compared to control rats. In humans increased levels of free NPY were found in obese women and not in their leaner counterparts, analysing human hypothalamus' for NPY concentration however is more difficult than rats.[31]During weaning in rats there is an early expression of gene mutations that increase hypothalamic release of NPY in rats, however in humans multiple genes are commonly associated with the results of obesity and metabolic syndrome.[31]In most obesity cases the increased secretion of NPY is a central / hypothalamic resistance to energy excess hormone signals such as leptin, that can be a result of a variety of reasons in the CNS. In rodents resistant to obesity when fed on an obesogenic diet they had a significantly lower amount of NPY receptor in the hypothalamus suggesting an increased activity of NPY neurons in obese rats meaning that the reduction in the release of NPY may be beneficial to the reduction of obesity incidence alongside the consumption of a healthy diet and exercise. This would need to be seen in human research before looking at this avenue of weight loss although currently there is some evidence that suggests NPY is a significant predictor in weight regain after weight loss to maintain old levels of energy storage.[31]

Furthermore, these factors correlate with each other. The sustained high levels of glucocorticosteroids stimulategluconeogenesis,which subsequently causes an increase of blood glucose that activates the release of insulin to regulate glucose levels by causing its reuptake and storage asglycogenin the tissues in the body. In the case of obesity, which researchers speculate to have a strong genetic and a dietary basis,insulin resistanceprevents high blood glucose regulation, resulting in morbid levels of glucose anddiabetes mellitus.[32]In addition, high levels of glucocorticosteroids causes an increase of NPY by directly activating type II glucocorticosteroids receptors (which are activated only by relatively high levels of glucocorticosteroids) and, indirectly, by abolishing the negative feedback ofcorticotropin-releasing factor(CRF) on NPY synthesis and release. Meanwhile, obesity-induced insulin resistance and the mutation of theleptin receptor(ObRb) results in the abolition of inhibition of NPYergic activity and ultimately food intake via other negative feedback mechanisms to regulate them. Obesity in rats was significantly reduced byadrenalectomy[33]orhypophysectomy.[34]

A study showed that neuropeptide Y can be used as a biosensor in early detection of childhood obesity[35]

Clinical significance

[edit]

Alcoholism

[edit]

The role of neuropeptide Y has gained substantial attention for its involvement withalcoholismdue to its diverse range of physiological effects.[36]NPY neurons have been shown to interact withdopaminergicreward andemotionpathwaysin thenucleus accumbensandamygdala,respectively. NPY expression levels andalcoholpreference have been shown to exhibit aninverse relationship.Expressionlevels are dependent on the brain area of interest. This indicates that baseline NPY levels could possibly influenceinnatealcohol preferences.[7]

Previous studies have identified NPY'sanxiolyticeffects to a possibletherapeutic drugtarget for alcoholism.[37]As stated before, NPY levels and ethanol intake show an inverse relationship, therefore, increasing NPY availability could decrease alcohol intake. By creating a chemicalantagonistfor a Y2 receptor that would indirectly act as anagonistand stimulate Y1 receptors, alcohol consumption was successfully decreased in rats.[36]Additionally, another similar study identified that NPY expression may be connected to behavioral regulation in relation toalcohol dependence.Administration of neuropeptide Y was found to reducebinge-drinkingbehavior.[38]Although, it has been shown that NPYgene expression,mRNA or neuropeptide levels are not influenced by long-term alcohol consumption, but changes do occur during withdrawal from alcohol. These findings show that neuropeptide Y has varying effects on alcohol consumption.[36]

Two results suggest that NPY might protect againstalcoholism:

  • knock-out micein which a type of NPY receptor has been removed show a higher voluntary intake of alcohol and a higher resistance to alcohol's sedating effects, compared to normal mice;[39]
  • thecommon fruit flyhas a neuropeptide that is similar to NPY, known asneuropeptide F.The levels of neuropeptide F are lowered in sexually frustrated male flies, and this causes the flies to increase their voluntary intake of alcohol.[40]

Stress and anxiety

[edit]

Neuropeptide Y is considered to be ananxiolyticendogenouspeptide and its levels can be modulated by stress. NPY has connections to the HPA axis and is believed to be necessary forstress modulation.[41]It has been shown that higher levels of the Y1 and Y5 receptors in theamygdalaresult in reduced level ofanxiety.[42]Additionally, the Y1 receptor has been linked to anxiolytic effects in theforebrainwhile Y2 has been associated with thepons.[11]

Conversely, higher levels of NPY may be associated withresilienceagainst and recovery fromposttraumatic stress disorder[43]and with dampening the fear response, allowing individuals to perform better under extreme stress.[44]

Studies ofmiceandmonkeysshow that repeatedstress—and a high-fat,high-sugardiet—stimulate the release of neuropeptide Y, causing fat to build up in theabdomen.Researchers believe that by manipulating levels of NPY, they could eliminate fat from areas where it was not desired and accumulate at sites where it is needed.[9][45]

See also

[edit]

References

[edit]
  1. ^abcGRCh38: Ensembl release 89: ENSG00000122585–Ensembl,May 2017
  2. ^abcGRCm38: Ensembl release 89: ENSMUSG00000029819–Ensembl,May 2017
  3. ^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^Heilig M, Widerlöv E (1995). "Neurobiology and clinical aspects of neuropeptide Y".Critical Reviews in Neurobiology.9(2–3): 115–136.PMID8581979.
  6. ^abDecressac M, Barker RA (December 2012). "Neuropeptide Y and its role in CNS disease and repair".Experimental Neurology.238(2): 265–272.doi:10.1016/j.expneurol.2012.09.004.PMID23022456.S2CID15088613.
  7. ^abcRobinson SL, Thiele TE (2017). "The Role of Neuropeptide y (NPY) in Alcohol and Drug Abuse Disorders".The Role of Neuropeptides in Addiction and Disorders of Excessive Consumption.International Review of Neurobiology. Vol. 136. pp. 177–197.doi:10.1016/bs.irn.2017.06.005.ISBN9780128124734.PMID29056151.
  8. ^abcTatemoto K (2004)."Neuropeptide Y and Related Peptides".In Michel MC (ed.).Neuropeptide Y: History and Overview.Handbook of Experimental Pharmacology. Vol. 162. Springer. pp. 2–15.ISBN9783540405818.
  9. ^abKuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, et al. (July 2007). "Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome".Nature Medicine.13(7): 803–811.doi:10.1038/nm1611.PMID17603492.S2CID25675166.
  10. ^Colmers WF, El Bahh B (March 2003)."Neuropeptide Y and Epilepsy".Epilepsy Currents.3(2): 53–58.doi:10.1046/j.1535-7597.2003.03208.x.PMC321170.PMID15309085.
  11. ^abKask A, Harro J, von Hörsten S, Redrobe JP, Dumont Y, Quirion R (May 2002). "The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y".Neuroscience and Biobehavioral Reviews.26(3): 259–283.doi:10.1016/s0149-7634(01)00066-5.PMID12034130.S2CID34688422.
  12. ^Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, et al. (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors".Pharmacological Reviews.50(1): 143–150.PMID9549761.
  13. ^Acuna-Goycolea C, Tamamaki N, Yanagawa Y, Obata K, van den Pol AN (August 2005)."Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide inhibition of identified green fluorescent protein-expressing GABA neurons in the hypothalamic neuroendocrine arcuate nucleus".The Journal of Neuroscience.25(32): 7406–7419.doi:10.1523/jneurosci.1008-05.2005.PMC6725307.PMID16093392.
  14. ^Kautz M, Charney DS, Murrough JW (May 2017). "Neuropeptide Y, resilience, and PTSD therapeutics".Neuroscience Letters.649:164–169.doi:10.1016/j.neulet.2016.11.061.PMID27913193.S2CID3821043.
  15. ^Dhamad A, Zampiga M, Greene ES, Sirri F, Dridi S (September 2021). "Neuropeptide Y and its receptors are expressed in chicken skeletal muscle and regulate mitochondrial function".General and Comparative Endocrinology.310:113798.doi:10.1016/j.ygcen.2021.113798.PMID33961876.
  16. ^abDecressac M, Wright B, David B, Tyers P, Jaber M, Barker RA, Gaillard A (March 2011). "Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis".Hippocampus.21(3): 233–238.doi:10.1002/hipo.20765.PMID20095007.S2CID4014094.
  17. ^Howell OW, Doyle K, Goodman JH, Scharfman HE, Herzog H, Pringle A, et al. (May 2005). "Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus".Journal of Neurochemistry.93(3): 560–570.doi:10.1111/j.1471-4159.2005.03057.x.PMID15836615.S2CID1531546.
  18. ^Malva JO, Xapelli S, Baptista S, Valero J, Agasse F, Ferreira R, Silva AP (December 2012). "Multifaces of neuropeptide Y in the brain--neuroprotection, neurogenesis and neuroinflammation".Neuropeptides.46(6): 299–308.doi:10.1016/j.npep.2012.09.001.PMID23116540.S2CID9366746.
  19. ^Hansel DE, Eipper BA, Ronnett GV (April 2001). "Neuropeptide Y functions as a neuroproliferative factor".Nature.410(6831): 940–944.Bibcode:2001Natur.410..940H.doi:10.1038/35073601.PMID11309620.S2CID4421740.
  20. ^Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, Polak JM (August 1983). "Neuropeptide Y distribution in the rat brain".Science.221(4613): 877–879.Bibcode:1983Sci...221..877A.doi:10.1126/science.6136091.PMID6136091.
  21. ^Morris BJ (December 1989). "Neuronal localisation of neuropeptide Y gene expression in rat brain".The Journal of Comparative Neurology.290(3): 358–368.doi:10.1002/cne.902900305.PMID2592617.S2CID36876107.
  22. ^Haas DA, George SR (October 1989). "Neuropeptide Y-induced effects on hypothalamic corticotropin-releasing factor content and release are dependent on noradrenergic/adrenergic neurotransmission".Brain Research.498(2): 333–338.doi:10.1016/0006-8993(89)91112-8.PMID2551461.S2CID36802464.
  23. ^Edwardson JA, Hough CA (April 1975). "The pituitary-adrenal system of the genetically obese (ob/ob) mouse".The Journal of Endocrinology.65(1): 99–107.doi:10.1677/joe.0.0650099.PMID167093.
  24. ^abcHanson ES, Dallman MF (April 1995). "Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis".Journal of Neuroendocrinology.7(4): 273–279.doi:10.1111/j.1365-2826.1995.tb00757.x.PMID7647769.S2CID25471741.
  25. ^abWhite BD, Dean RG, Edwards GL, Martin RJ (May 1994). "Type II corticosteroid receptor stimulation increases NPY gene expression in basomedial hypothalamus of rats".The American Journal of Physiology.266(5 Pt 2): R1523–R1529.doi:10.1152/ajpregu.1994.266.5.R1523.PMID8203629.
  26. ^King PJ, Widdowson PS, Doods HN, Williams G (August 1999). "Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices".Journal of Neurochemistry.73(2): 641–646.doi:10.1046/j.1471-4159.1999.0730641.x.PMID10428060.S2CID8022493.
  27. ^Pomonis JD, Levine AS, Billington CJ (July 1997)."Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade of neuropeptide Y-induced feeding revealed by c-fos expression".The Journal of Neuroscience.17(13): 5175–5182.doi:10.1523/JNEUROSCI.17-13-05175.1997.PMC6573318.PMID9185555.
  28. ^King PJ, Williams G, Doods H, Widdowson PS (May 2000). "Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release".European Journal of Pharmacology.396(1): R1–R3.doi:10.1016/S0014-2999(00)00230-2.PMID10822055.
  29. ^Beck B (July 2006)."Neuropeptide Y in normal eating and in genetic and dietary-induced obesity".Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.361(1471): 1159–1185.doi:10.1098/rstb.2006.1855.PMC1642692.PMID16874931.
  30. ^Dryden S, Pickavance L, Frankish HM, Williams G (September 1995). "Increased neuropeptide Y secretion in the hypothalamic paraventricular nucleus of obese (fa/fa) Zucker rats".Brain Research.690(2): 185–188.doi:10.1016/0006-8993(95)00628-4.PMID8535835.S2CID1857168.
  31. ^abcMinor RK, Chang JW, de Cabo R (February 2009)."Hungry for life: How the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction".Molecular and Cellular Endocrinology.299(1): 79–88.doi:10.1016/j.mce.2008.10.044.PMC2668104.PMID19041366.
  32. ^Wilcox G (May 2005)."Insulin and insulin resistance".The Clinical Biochemist. Reviews.26(2): 19–39.PMC1204764.PMID16278749.
  33. ^Yukimura Y, Bray GA (1978). "Effects of adrenalectomy on body weight and the size and number of fat cells in the Zucker (fatty) rat".Endocrine Research Communications.5(3): 189–198.doi:10.1080/07435807809083752.PMID747998.
  34. ^Powley TL, Morton SA (April 1976). "Hypophysectomy and regulation of body weight in the genetically obese Zucker rat".The American Journal of Physiology.230(4): 982–987.doi:10.1152/ajplegacy.1976.230.4.982.PMID1267030.
  35. ^Özcan B, Sezgintürk MK (December 2022)."Fabrication of an ultrasensitive and single-use graphite paper based immunosensor for Neuropeptide Y detection: A promising biosensing system for early detection of childhood obesity".Materials Today Communications.33:104797.doi:10.1016/j.mtcomm.2022.104797.S2CID253229487.
  36. ^abcCiccocioppo R, Gehlert DR, Ryabinin A, Kaur S, Cippitelli A, Thorsell A, et al. (November 2009)."Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond".Alcohol.43(7): 491–498.doi:10.1016/j.alcohol.2009.08.003.PMC2804869.PMID19913192.
  37. ^Thorsell A, Mathé AA (2017)."Neuropeptide Y in Alcohol Addiction and Affective Disorders".Frontiers in Endocrinology.8:178.doi:10.3389/fendo.2017.00178.PMC5534438.PMID28824541.
  38. ^Sparrow AM, Lowery-Gionta EG, Pleil KE, Li C, Sprow GM, Cox BR, et al. (May 2012)."Central neuropeptide Y modulates binge-like ethanol drinking in C57BL/6J mice via Y1 and Y2 receptors".Neuropsychopharmacology.37(6): 1409–1421.doi:10.1038/npp.2011.327.PMC3327846.PMID22218088.
  39. ^Thiele TE, Koh MT, Pedrazzini T (February 2002)."Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor".The Journal of Neuroscience.22(3): RC208.doi:10.1523/JNEUROSCI.22-03-j0006.2002.PMC6758511.PMID11826154.
  40. ^"Deprived of Sex, Jilted Flies Drink More Alcohol".UCSF News Center.March 15, 2012.
  41. ^Reichmann F, Holzer P (February 2016)."Neuropeptide Y: A stressful review".Neuropeptides.55:99–109.doi:10.1016/j.npep.2015.09.008.PMC4830398.PMID26441327.
  42. ^Dumont Y, Quirion R (December 2014). "Neuropeptide Y pathways in anxiety-related disorders".Biological Psychiatry.76(11): 834–835.doi:10.1016/j.biopsych.2014.09.015.PMID25439997.S2CID38147315.
  43. ^Yehuda R, Brand S, Yang RK (April 2006). "Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping".Biological Psychiatry.59(7): 660–663.doi:10.1016/j.biopsych.2005.08.027.PMID16325152.S2CID33677746.
  44. ^Steenhuysen J (February 16, 2009)."Research shows why some soldiers are cool under fire".Archived fromthe originalon February 19, 2009.RetrievedFebruary 17,2009.
  45. ^Maugh TH (July 2, 2007)."Research points to way to eliminate belly fat".Chicago Tribune.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Neuropeptide_Y&oldid=1213553726"